Rationale: Houshiheisan (HSHS), a classic prescription in traditional Chinese medicine (TCM), has remarkable efficacy in the treatment of ischemic stroke.
Objective: To investigate the pro-angiogenic effect and molecular mechanism of HSHS for stroke recovery.
Methods And Results: The rat permanent middle cerebral artery occlusion (pMCAO) model was constructed by suture method, HSHS (5.25 or 10.5 g/kg) and Ginaton (28 mg/kg) treatment was intragastrically administrated at 6 h after modeling which remained for 7 consecutive days. Pathological evaluation conducted by Hematoxylin-Eosin (HE) staining and the results showed that HSHS alleviated blood vessel edema, reduced the damage to blood vessels and neurons in the ischemic areas. Immunostaining, quantitative real-time fluorescence PCR results showed that HSHS up-regulated pro-angiogenic factors including platelet endothelial cell adhesion molecule-1 (cluster of differentiation 31 (CD31)), vascular endothelial growth factor (VEGF), vascular endothelial growth factor A (VEGFA), VEGF receptor 2 (VEGFR2), angiopoietin-1 (Ang-1), while down-regulated angiopoietin-2 (Ang-2), stromal cell derived factor-1 (SDF-1), and cxc chemokine receptor 4 (CXCR4) expression in infarct rat cortex, and similar results were obtained in subsequent Western blot experiment. Furthermore, CCK8 assay and transwell migration assay were performed to assess cell proliferation, migration, and tube formation. The medicated serum (MS) of HSHS appeared to have beneficial effects for immortalized human umbilical vein cells (Im-HUVECs) on proliferation and migration after persistence hypoxia. Western blot analysis revealed that the expression of hypoxia inducible factor-1α (HIF-1α), VEGFA, Ang-1, Ang-2, and CXCR4 were significantly up-regulated while Ang-2 was down-regulated by HSHS MS treatment compared with vehicle group in vitro.
Conclusion: The present study suggests a novel application of HSHS as an effective angiogenic formula for stroke recovery.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822506 | PMC |
| http://dx.doi.org/10.1042/BSR20191006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Developmental Outcomes of Very Preterm Infants Conceived Through In Vitro Fertilization.
Arch Med Res
December 2024
Department of Pediatrics, Southern Illinois University School of Medicine, Springfield, IL, USA.
Objective: To compare in-hospital and neurodevelopmental (ND) outcomes between very preterm infants conceived spontaneously and those conceived utilizing in vitro fertilization (IVF).
Study Design: A 10-year retrospective study of a large regional, mixed urban and rural population was conducted. IVF conceived infants born <32 0/7 weeks gestational age (GA) were matched 1:2 to control patients who did not undergo any documented assisted reproductive technology (ART) based on GA, birth weight and gender.
Extracellular vesicles derived from endothelial progenitor cells modified by Houshiheisan promote angiogenesis and attenuate cerebral ischemic injury via miR-126/PIK3R2.
Sci Rep
November 2024
Department of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
Angiogenesis following cerebral ischemia is crucial for restoring blood supply to the ischemic region. Extracellular vesicles (EVs) derived from endothelial progenitor cells (EPCs) offer potential therapeutic benefits in the treatment of cerebral ischemia. Houshiheisan (HSHS) has been shown to improve clinical outcomes in ischemic stroke patients, reduce cerebral ischemic damage in rats, and protect endothelial cells.
View Article and Find Full Text PDFClinical characteristics and impairment of activities of daily living among patients with myasthenia gravis with differing degrees of muscle weakness: a real-world study of patients in the US and five European countries.
BMC Neurol
October 2024
HSHS Medical Group Multispecialty Care - St. Elizabeth's, O'Fallon, IL, USA.
Article Synopsis
- A study analyzed clinical characteristics of myasthenia gravis (MG) patients using real-world data from a multinational survey conducted in 2020.
- Results showed that patients in MGFA class I had less impairment in daily activities compared to classes II and III/IV, although some within class I still reported serious symptoms like bulbar issues and shortness of breath.
- Despite variations in symptom severity across MGFA classes, all patients faced risks for myasthenic crises, hospitalization, and mental health issues.
Patient and care partner perspectives and preferences related to myasthenia gravis treatment: A qualitative study.
Health Sci Rep
September 2024
HSHS Medical Group Multispecialty Care O'Fallon Illinois USA.
Background And Aims: Due to the high symptom and treatment burden in myasthenia gravis (MG), understanding patient and care partner perspectives and preferences is crucial.
Methods: This study used voice analysis and virtual focus groups to understand patient and care partner experiences with MG-related symptoms, treatments, and preferences. The voice analysis via social media listening used artificial intelligence-powered tools to gather and structure public digital conversations on MG.
Copper Deficiency Mimicking Myelodysplastic Syndrome: A Case Report.
Cureus
August 2024
Hematology and Oncology, Southern Illinois University School of Medicine, Springfield, USA.
Copper deficiency can mimic myelodysplastic syndrome, a group of heterogeneous hematopoietic disorders characterized by peripheral cytopenias, with potential progression to bone marrow failure and acute myeloid leukemia. We present the case of an 83-year-old female with a history of Graves' disease, early-stage hormone receptor-positive breast cancer, hypertension, and glaucoma, who presented with fatigue and progressive lower extremity weakness. Laboratory tests revealed macrocytic anemia, neutropenia, and lymphopenia, with normal platelet counts.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!